254 related articles for article (PubMed ID: 36068377)
1. A potential association between obesity and reduced effectiveness of COVID-19 vaccine-induced neutralizing humoral immunity.
Faizo AA; Qashqari FS; El-Kafrawy SA; Barasheed O; Almashjary MN; Alfelali M; Bawazir AA; Albarakati BM; Khayyat SA; Hassan AM; Alandijany TA; Azhar EI
J Med Virol; 2023 Jan; 95(1):e28130. PubMed ID: 36068377
[TBL] [Abstract][Full Text] [Related]
2. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
3. Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies.
Kohmer N; Rabenau HF; Ciesek S; Krämer BK; Göttmann U; Keller C; Rose D; Blume C; Thomas M; Lammert A; Lammert A
Nephrol Dial Transplant; 2022 May; 37(6):1132-1139. PubMed ID: 35099023
[TBL] [Abstract][Full Text] [Related]
4. Lack of Evidence on Association between Iron Deficiency and COVID-19 Vaccine-Induced Neutralizing Humoral Immunity.
Faizo AA; Bawazir AA; Almashjary MN; Hassan AM; Qashqari FS; Barefah AS; El-Kafrawy SA; Alandijany TA; Azhar EI
Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851205
[TBL] [Abstract][Full Text] [Related]
5. Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the "Green Pass" Policy.
Polvere I; Parrella A; Zerillo L; Voccola S; Cardinale G; D'Andrea S; Madera JR; Stilo R; Vito P; Zotti T
Front Immunol; 2022; 13():833085. PubMed ID: 35634315
[TBL] [Abstract][Full Text] [Related]
6. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
Casas Fischer R
Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
[TBL] [Abstract][Full Text] [Related]
7. [COVID-19 vaccination at the University of Alicante (Spain): detection of neutralizing antibodies against SARS-CoV-2 by rapid serological test, a cross-sectional study].
Montagud AC; Vicente-Alcalde N; Gabaldón-Bravo EM; Hurtado-Sánchez JA; Montagud E; Egoavil CM; Chavarría-Alarcón E; Caballero P; Tuells J
Rev Esp Salud Publica; 2023 Dec; 97():. PubMed ID: 38126466
[TBL] [Abstract][Full Text] [Related]
8. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of Both Humoral and Cellular Immunities Could Early Predict COVID-19 Vaccine Efficacy Against the Different SARS-CoV2 Variants.
Vogrig M; Berger AE; Bourlet T; Waeckel L; Haccourt A; Chanavat A; Hupin D; Roche F; Botelho-Nevers E; Pozzetto B; Paul S
J Clin Immunol; 2023 Jan; 43(1):31-45. PubMed ID: 36006568
[TBL] [Abstract][Full Text] [Related]
10. Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses.
Almendro-Vázquez P; Chivite-Lacaba M; Utrero-Rico A; González-Cuadrado C; Laguna-Goya R; Moreno-Batanero M; Sánchez-Paz L; Luczkowiak J; Labiod N; Folgueira MD; Delgado R; Paz-Artal E
Front Immunol; 2022; 13():981350. PubMed ID: 36059485
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals.
Hayer J; Urlaub E
Microbiol Spectr; 2022 Jun; 10(3):e0270921. PubMed ID: 35575594
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal Follow-Up of the Immunity to SARS-CoV-2 in Health Care Workers in Argentina: Persistence of Humoral Response and Neutralizing Capacity after Sputnik V Vaccination.
Castro EF; Acosta J; Moriena L; Rios Medrano M; Tejerina Cibello M; Codino E; Taborda MÁ; Álvarez DE; Cavatorta AL
mSphere; 2023 Jun; 8(3):e0066222. PubMed ID: 37070983
[TBL] [Abstract][Full Text] [Related]
13. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
[TBL] [Abstract][Full Text] [Related]
14. NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens.
Hielscher F; Schmidt T; Klemis V; Wilhelm A; Marx S; Abu-Omar A; Ziegler L; Guckelmus C; Urschel R; Sester U; Widera M; Sester M
J Clin Virol; 2022 Dec; 157():105321. PubMed ID: 36279695
[TBL] [Abstract][Full Text] [Related]
15. What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees?
Ravlić S; Kurtović T; Cvetko Krajinović L; Hećimović A; Miloš M; Mateljak Lukačević S; Markotić A; Halassy B
Hum Vaccin Immunother; 2023 Dec; 19(3):2270310. PubMed ID: 37905722
[TBL] [Abstract][Full Text] [Related]
16. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
17. Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine - A Prospective Observational Study.
Herzberg J; Fischer B; Becher H; Becker AK; Honarpisheh H; Guraya SY; Strate T; Knabbe C
Front Immunol; 2022; 13():896151. PubMed ID: 35844588
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of residual humoral immune response against SARS-CoV-2 by a surrogate virus neutralization test (sVNT) 9 months after BNT162b2 primary vaccination.
Pezzati L; Milazzo L; Carrozzo G; Kullmann C; Oreni L; Beltrami M; Caronni S; Lai A; Caberlotto L; Ottomano C; Antinori S; Ridolfo AL
J Infect Chemother; 2023 Jun; 29(6):624-627. PubMed ID: 36914095
[TBL] [Abstract][Full Text] [Related]
19. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
20. Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccination.
Iancovici L; Khateeb D; Harel O; Peri R; Slobodin G; Hazan Y; Melamed D; Kessel A; Bar-On Y
Rheumatology (Oxford); 2022 Aug; 61(8):3439-3447. PubMed ID: 34849628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
